Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD.
Aged
Bacteria
/ genetics
Bacterial Load
Case-Control Studies
Female
Host-Pathogen Interactions
Humans
Inflammation Mediators
/ analysis
Lung
/ immunology
Male
Middle Aged
Pulmonary Disease, Chronic Obstructive
/ diagnosis
Risk Factors
Smoking
/ adverse effects
Sputum
/ immunology
alpha 1-Antitrypsin Deficiency
/ complications
COPD
alpha-1 antitrypsin deficiency
chronic airway inflammation
respiratory disability
sputum
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
02
2019
accepted:
10
07
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
14
4
2020
Statut:
epublish
Résumé
Airway inflammation may drive the progression of chronic obstructive pulmonary disease (COPD) associated with alpha-1 antitrypsin deficiency (AATD), but the relationship between airway microbiota and inflammation has not been investigated. We studied 21 non-treated AATD (AATD-noT) patients, 20 AATD-COPD patients under augmentation therapy (AATD-AT), 20 cigarette smoke-associated COPD patients, 20 control healthy smokers (CS) and 21 non-smokers (CON) with normal lung function. We quantified sputum inflammatory cells and inflammatory markers (IL-27, CCL3, CCL5, CXCL8, LTB AATD-AT patients were younger but had similar spirometric and DLCO values compared to cigarette smoke-associated COPD, despite a lower burden of smoking history. Compared to cigarette smoke-associated COPD, AATD-noT and AATD-AT patients had lower sputum neutrophil levels ( Compared to cigarette smoke-associated COPD, AATD-AT (COPD) patients have a distinct airway inflammatory and microbiological profile. The decreased sputum bacterial load and IL-27 levels in AATD-AT patients suggests that augmentation therapy play a role in these changes.
Sections du résumé
Background
Airway inflammation may drive the progression of chronic obstructive pulmonary disease (COPD) associated with alpha-1 antitrypsin deficiency (AATD), but the relationship between airway microbiota and inflammation has not been investigated.
Methods
We studied 21 non-treated AATD (AATD-noT) patients, 20 AATD-COPD patients under augmentation therapy (AATD-AT), 20 cigarette smoke-associated COPD patients, 20 control healthy smokers (CS) and 21 non-smokers (CON) with normal lung function. We quantified sputum inflammatory cells and inflammatory markers (IL-27, CCL3, CCL5, CXCL8, LTB
Results
AATD-AT patients were younger but had similar spirometric and DLCO values compared to cigarette smoke-associated COPD, despite a lower burden of smoking history. Compared to cigarette smoke-associated COPD, AATD-noT and AATD-AT patients had lower sputum neutrophil levels (
Conclusions
Compared to cigarette smoke-associated COPD, AATD-AT (COPD) patients have a distinct airway inflammatory and microbiological profile. The decreased sputum bacterial load and IL-27 levels in AATD-AT patients suggests that augmentation therapy play a role in these changes.
Identifiants
pubmed: 31686800
doi: 10.2147/COPD.S207203
pii: 207203
pmc: PMC6709647
doi:
Substances chimiques
Inflammation Mediators
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1879-1893Informations de copyright
© 2019 Balbi et al.
Déclaration de conflit d'intérêts
This study was funded by Istituti Clinici Scientifici Maugeri, IRCCS and by Grifols Inc. Grifols Inc. with a two-year grant. Grifols funding included laboratory supplies, travel expenses for collecting samples around the Country and a fellowship for a Ph.D. The authors report no other conflicts of interest in this work.
Références
Trends Mol Med. 2014 Feb;20(2):105-15
pubmed: 24380646
PLoS One. 2015 Sep 11;10(9):e0137651
pubmed: 26360023
Respir Res. 2006 Nov 18;7:136
pubmed: 17112387
Clin Chest Med. 2014 Mar;35(1):71-86
pubmed: 24507838
J Clin Invest. 1991 Sep;88(3):891-7
pubmed: 1653278
Eur J Immunol. 2012 Dec;42(12):3280-90
pubmed: 22965735
Chest. 2000 Nov;118(5):1480-5
pubmed: 11083705
N Engl J Med. 1987 Apr 23;316(17):1055-62
pubmed: 3494198
COPD. 2015 May;12 Suppl 1:52-7
pubmed: 25938293
Lancet. 2015 Jul 25;386(9991):360-8
pubmed: 26026936
Thorax. 2001 Jan;56(1):36-41
pubmed: 11120902
Thorax. 2014 Jun;69(6):516-24
pubmed: 24430176
Eur Respir J. 2016 Jan;47(1):35-8
pubmed: 26721962
Eur Respir J. 2017 Nov 30;50(5):
pubmed: 29191952
J Clin Microbiol. 2003 Sep;41(9):4298-303
pubmed: 12958260
Am J Respir Crit Care Med. 2011 May 1;183(9):1176-86
pubmed: 21257786
Nat Commun. 2017 Sep 19;8(1):602
pubmed: 28928459
Eur Respir J. 2000 May;15(5):886-90
pubmed: 10853853
Eur Respir J. 2012 Sep;40(3):561-9
pubmed: 22700846
EMBO Mol Med. 2014 Jan;6(1):120-40
pubmed: 24408967
Cell. 2014 Mar 27;157(1):121-41
pubmed: 24679531
Thorax. 2009 Nov;64(11):968-75
pubmed: 19703829
Cytokine. 2018 Jul;107:85-92
pubmed: 29221667
Int J Chron Obstruct Pulmon Dis. 2016 Mar 01;11:445-53
pubmed: 27042037
Curr Med Chem. 2013;20(35):4317-49
pubmed: 24059236
Respir Med. 2006 Jun;100(6):1094-9
pubmed: 16257194
Am J Respir Crit Care Med. 2007 Dec 15;176(12):1215-21
pubmed: 17872489
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1646-52
pubmed: 7952628
Thorax. 2016 Sep;71(9):795-803
pubmed: 27146202
Am J Respir Crit Care Med. 2000 Dec;162(6):2069-72
pubmed: 11112116
Am J Respir Crit Care Med. 2002 Jun 1;165(11):1494-8
pubmed: 12045122
Am J Respir Crit Care Med. 1998 Oct;158(4):1277-85
pubmed: 9769292
Eur Respir J. 2005 Apr;25(4):612-7
pubmed: 15802333
Eur Respir J. 2017 May 23;49(5):
pubmed: 28536249
Sci Rep. 2016 Mar 31;6:23745
pubmed: 27030383
Eur Respir J. 2007 Feb;29(2):240-50
pubmed: 17050563
Ann N Y Acad Sci. 2015 Mar;1340:55-64
pubmed: 25639503
J Clin Invest. 1992 May;89(5):1478-84
pubmed: 1569186